EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome



Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome



American Journal of Gastroenterology 99(11): 2195-2203



OBJECTIVES: To assess long-term safety and efficacy of alosetron in women with severe, chronic diarrhea-predominant IBS and in a subset having more frequent urgency (i.e., bowel urgency at least 10 of 14 days during screening). METHODS: Randomized patients received either alosetron 1 mg (n = 351) or placebo (n = 363) twice daily during a 48-wk, double-blind study. The primary endpoint was the 48-wk average rate of adequate relief of IBS pain and discomfort.

(PDF emailed within 0-6 h: $19.90)

Accession: 012273599

Download citation: RISBibTeXText

PMID: 15555002

DOI: 10.1111/j.1572-0241.2004.30509.x



Related references

Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Review of Gastroenterology & Hepatology 4(1): 13-29, 2010

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clinical Gastroenterology and Hepatology 2(8): 675-682, 2004

Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome. Clinical and Experimental Gastroenterology 6: 123-128, 2013

Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. Therapeutic Advances in Gastroenterology 3(3): 165-172, 2010

Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes. Current Medical Research and Opinion 27(3): 503-512, 2011

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. American Journal of Gastroenterology 96(9): 2662-2670, 2001

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. American Journal of Gastroenterology 96(2): 455-459, 2001

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. American Journal of Gastroenterology 97(12): 3139-3146, 2002

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Archives of Internal Medicine 161(14): 1733-1740, 2001

Alosetron retards small bowel and overall colonic transit in diarrhea-predominant irritable bowel syndrome. Gastroenterology 118(4 Suppl 2 Part 1): AGA A848, April, 2000

Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome. Women's Health 3(1): 15-27, 2007

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. American Journal of Gastroenterology 102(8): 1709-1719, 2007

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 355(9209): 1035-1040, 2000

Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. American Journal of Gastroenterology 98(12): 2705-2711, 2003